Editas Medicine says that it will be testing CRISPR-based gene editing in people by 2017, according to Technology Review.

At the EmTech conference, CEO Katrine Bosley said the startup — co-founded by the Broad Institute's Feng Zhang — plans to start a clinical trial within two years to test the use of gene editing to treat Leber congenital amaurosis, a rare form of blindness affecting the retina.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.